News

Prices of 869 formulations to go up by 3.44 per cent, says NPPA

Views: 812

drugs

The Government has announced that the prices of 869 formulations including antibiotics, cancer and cardiovascular disease treatment drugs and two types of coronary stents will go up by 3.44 per cent.

The development follows a price revision as per annual wholesale Price Index (WPI), the drug pricing regulator, NPPA said in separate notifications on Monday.

Once the new price comes into effect, bare metal stents will cost Rs 7,923 while drug eluting stents (DES), including metallic DES and bioresorbable vascular scaffold / biodegradable stents will cost Rs 28,849.

The National Pharmaceutical Pricing Authority (NPPA) revised prices of 859 scheduled formulations, which included antibiotics such as combination of Amoxicillin (A) and Clavulanic acid (B) used in treatment of bacterial infections; docetaxel that is used to treat variety of cancers and atorvastatin, a cholesterol lowering drug which is also used for prevention cardiovascular diseases.

The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.

It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

The regulator is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

Most Popular

 

 


 

 

Get Heard Portal

 

eHealth Event Report

 

 

To Top